
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.

Biotechnology

Research

Transcend Therapeutics

Blake Mandell

Professor Paul William Miller Kctj M.D. Dmh Mrcpsych Frsa

Stephanie Galinos

Sarah Olmstead

Jennifer Schmidt

Megan Kelly

Amanda Jones

Martin Stogniew

Benjamin Kelmendi

The Leadership Team at Transcend Therapeutics is responsible for guiding the company's strategic vision and overseeing the development of innovative psychoactive medicines. This team, composed of experienced leaders in clinical development and research, collaborates to advance clinical trials, secure funding, and ensure that the company's products effectively address the needs of patients with neuropsychiatric disorders. Their collective expertise drives the company’s mission to create accessible treatment options for those suffering from conditions like PTSD and depression.

Leadership Team

Clinical Research Team

Leadership Team

About

Team members

Other teams at Transcend Therapeutics

Clinical Research Team